Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021



Rating:

Share or cite this content

Citations should be made in the following way:
Emily M. Hartsell, Mark N. Gillespie, Raymond J. Langley. Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies?. Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021

Member's Comments

No comment yet.

Related content which might interest you: Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19 Source: ERJ Open Res, 6 (4) 00405-2020; 10.1183/23120541.00405-2020 Year: 2020 COPD mechanisms: novel aspects and implications for new therapies Source: ERS Live 2007 Year: 2007 COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020 Year: 2020 A combinational approach to optimize biomarkers efficacy in identifying patients with sarcoidosis and monitoring respiratory functional worsening Source: Annual Congress 2012 - Diffuse parenchymal lung disease IV Year: 2012 Genetic studies as a tool for identifying novel potential targets for treatment of COPD Source: Eur Respir J, 50 (5) 1702042; 10.1183/13993003.02042-2017 Year: 2017 Lots of promising targets and biomarkers, but how can we deliver the next generation of severe asthma trials? Source: International Congress 2019 – Beyond T2 mechanisms in asthma: who are the other players? Year: 2019 Translational research approaches for finding new therapeutic targets involved in viral-induced asthma and COPD exacerbation Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014 Interference RNA as a new tool and possible future therapy for inflammatory lung disease Source: Lung Science Conference 2005 - Evidence-based medicine for respiratory disease with special emphasis on inflammatory processes Year: 2005 COPD – will new insights into molecular pathology define new therapies? Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014 Sputum induction for assessment of biomarkers in early development of new drugs for respiratory disease in a proof of concept setting Source: International Congress 2016 – Airway biomarkers Year: 2016 Targeting the arginase pathway: potential developments as new avenues for treatment Source: Annual Congress 2004 - Arginase: a novel target and marker for asthma? Year: 2004 Targeting intermittent hypoxia downstream pathways for biomarker discovery and new treatment perspectives in cutaneous melanoma Source: Eur Respir J, 53 (2) 1802444; 10.1183/13993003.02444-2018 Year: 2019 Applying new respiratory function technologies to the elderly and the potential of future lung regeneration Source: Virtual Congress 2020 – Lung health and respiratory function at all ages Year: 2020 Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities Source: Eur Respir J 2014; 44: 513-522 Year: 2014 What new biomarkers are on the horizon for severe exacerbations? Source: Research Seminar 2021 – Unravelling severe exacerbations of COPD – CICERO an ERS CRC Year: 2021 The consequences of novel insights into the pathophysiology of asthma for its treatment Source: Annual Congress 2008 - Should asthma no longer be considered an allergic disease? Year: 2008